The aim of this study is to investigate the effectiveness of the drug letrozole on your tumor. The drug is not yet a standard medication, so it is ethically justifiable not to give the drug to all patients and we have opted for a so-called randomized study design. This means that a computer program is used to randomly allocate 50% of the patients to receive treatment with letrozole and 50% of the patients to receive a placebo. The medication is administered as a daily tablet for a minimum of 1.5 years and a maximum of up to 5 years.
Aim of the study
The aim of the MATAO study is to investigate a specific treatment for ovarian cancer that explicitly carries estrogen receptors on the tumor surface. It is being investigated whether letrozole, a drug that is routinely used in the treatment of breast cancer, can also prevent a relapse in this type of ovarian cancer.
Who can take part?
Ovarian cancer
Procedure
Inclusion in the study via randomization, i.e. a computer program randomly decides whether you receive the drug letrozole or placebo. Neither you nor your treatment team know whether you are receiving the study drug letrozole or placebo (double-blind design)
Compensation
None
Original study name
MATAO: MAintenance therapy/ maintenance therapy with aromatase inhibitors for patients with epithelial ovarian cancer: a randomized double-blind placebo-controlled multicenter phase III study. (ENGOT-ov54/Swiss-GO-2/MATAO)
BASEC number
2020-00148
Sponsors